Zydus Cadila receives final approval for Felbamate Tablets

31 May 2017 Evaluate

Zydus Cadila has received the final approval from the U.S. Food and Drug Administration (USFDA) to market Felbamate Tablets USP in strengths of 400 mg and 600 mg. Felbamate is an oral drug used to treat seizures in people with epilepsy. It will be produced at the group's formulations manufacturing facility at the Pharma SEZ in Ahmedabad. The group now has more than 115 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Zydus Lifesciences Share Price

917.45 -10.65 (-1.15%)
24-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1737.50
Dr. Reddys Lab 1266.35
Cipla 1496.35
Zydus Lifesciences 917.45
Lupin 2109.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×